Product Description
VRON-0200 is designed with the goal of providing a functional cure for chronic HBV infection. While the virus itself stimulates expansion of HBV-specific CD8+ T cells, they soon become exhausted, placing limits on their ability to proliferate and control the virus. VRON-0200, through checkpoint modification, is able to mitigate this exhaustion by lowering the activation threshold and stimulating T cells to sub-dominant epitopes that are not activated by HBV infection, which promotes further CD8+ T cell expansion and viral control. (Sourced from: https://www.viriontx.com/pipeline/vron-0200/#1646219869184-55df2028-9b6a)
Mechanisms of Action: Vaccine
Novel Mechanism: No
Modality: Vaccine
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Virion Therapeutics
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Hong Kong, New Zealand
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Hepatitis B, Chronic
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NCT06070051 | P1 |
Recruiting |
Hepatitis B, Chronic |
2025-11-30 |